TLR4 and prostate neoplasm: Inhibition of the rapid endocytotic uptake of Ahsg was demonstrated in TLR4-knockdown prostate tumor cells treated with a TLR4-specific inhibitor (CLI-095), which inhibited tumor cell adhesion and invasion through Matrigel [33].